The effects of hyperprolactinemia
It is well documented that hyperprolactinemia results in anovulatory conditions and that hyperprolactinemic women do not show the luteinizing hormone (LH) release after estrogen injection that is observed in normal cycling women (Glass et al., 1975 ; Aono et al., 1976 ; L'Hermite et al., 1978) . Normalization of plasma prolactin (PRL) following bromocriptine treatment (Aono et al., 1979) and removal of prolactinomas by transsphenoidal surgery (Koike et al., 1982) restores the LH surge after estrogen administration and the ovulatory cycle. These findings suggest that the impaired release of LH in response to estrogen may be one reason for anovulation in hyperprolactinemic women. It is not clear whether PRL inhibits the secretion of pituitary LH directly or through impaired hypothalamic LH-releasing hormone (LH-RH) secretion. We recently observed the induction of a plasma LH-RH peak after estrogen injection in normal cycling women (Miyake et al., 1983) .
In the present study, we investigated the effects of sulpiride-induced hyperprolactinemia on the release of LH-RH in response to estrogen injection.
Materials and Methods
In the control cycle, five normal cycling women aged 21 to 23 were injected with 20 mg of conjugated estrogens, Premarin(R) (Ayerst Labs., Rouses Point, N.Y.), on the morning of the 7th day of the cycle. Blood samples were taken between 8 and 9 a.m. from the 3rd to 7th day of the cycle and 0, 8, 24, 32, 40, 48, 56 and 72 h after Premarin injection and were stored at until assayed. Two months later, the same normal women received 200 mg of oral sulpiride daily for 8 days from the 3rd day of the cycle, and the same protocol as the control cycle was applied (sulpiride treated cycle). Informed consent of the volunteers to participate in the study was obtained. Plasma PRL levels in the morning samples taken from the 3rd to 10th day of the cycle were determined by RIA (Aono et al., 1976) . Plasma levels of LH-RH and LH in samples taken from 0 to 72 h after Premarin injection were determined by specific RIAs (Aono et al., 1972 Miyake et al., 1980 . Plasma levels of FSH and estradiol on the morning of the 7th day were also assayed by RIAs (Aono et al., 1972 and 1978) . The sensitivities and intraassay coefficients of variation of the assays were 0.6 pg/tube and 13.8% for LH-RH, 0.1 mIU/tube of the 2nd IRP-HMG and 13.3% for LH, 0.2 mIU/ tube and 9.0% for FSH, 2.0 ng/tube and 4.3% for PRL, and 10.0 pg/tube and 4.0% for estradiol respectively.
Statistical analyses of data were performed by split-plot type analysis of variance or Student's t-test. cycle gradually increased and reached a sharp peak of 154% above the preinjection level 40 h after Premarin injection. In the sulpiride treated cycle, no significant increase in LH-RH was observed during this period. The increase in LH-RH at 32 h and 40 h was significantly (p <0.05 and p <0.01) lower in the sulpiride treated cycle than in the control cycle. In the control cycle, the LH level showed a transient decrease with a rebound increase to 175% at 48 h and 99% at 56 h, but in the sulpiride treated cycle, it showed only a slight increase at 48 h. The increases in LH 48 h and 56 h after Premarin injection were significantly (p <0.01) lower in the sulpiride cycle than in the control cycle.
Discussion
We recently reported that in normal cycling women plasma immunoreactive LH-RH showed a sharp peak 32 h after iv administration of conjugated estrogens during the mid-follicular phase (Miyake et al., 1983) . We found that LH was significantly suppressed from 6 h to 42 h after the injection and then showed a rebound increase with a peak at 56 h. The present results are consistent with these previous data.
It has been reported that in hyperprolactinemic patients, the gonadotropin response to clomiphene (Thorner et al., 1974 ; Bohnet et al., 1976) and LH responses to estrogen (Glass et al., 1975 ; Aono et al., 1976 ; L'Hermite et al., 1978) and pulsatile LH secretion (Bohnet et al., 1976) are generally impaired, although tonic secretion of gonadotropin is well maintained (Aono et al., 1976 ; Bohnet et al., 1976 ; Healy et al., 1977) . This impaired gonadotropin secretion is restored by normalization of the PRL level by bromocriptine treatment (Asfour et al., 1977 ; Aono et al., 1979) and transsphenoidal surgery to remove prolactinomas (Koike et al., 1982) . Hokfelt and Fuxe (1972) ob-served that PRL causes a dose-dependent increase in the turnover of dopamine in median eminence neurons. Dopamine seems to exert its inhibitory action on LH-RH neurons (Gudelsky et al., 1976 ; Chatani et al., 1983) . From these findings, it has been postulated that hyperprolactinemia may disturb the hypothalamic function involved in the positive feedback effect of estrogen on LH secretion. The present study indicates that sulpiride-induced hyperprolactinemia suppresses the release of both LH-RH and LH after intravenous estrogen administration. These data suggest that the impaired positive feedback effect of estrogen on LH release in anovulatory women with hyperprolactinemia may be caused, at least in part, by disturbed LH-RH release.
It has been reported that an increased level of PRL blocks the action of gonadotropins at the ovarian level (McNatty et al., 1974 ; Wang et al., 1980) , and it is conceivable that inadequate estrogen production by the ovary impairs the positive feedback effect of estrogen on LH release. Indeed, in the present study the estradiol level was found to be lowered significantly by sulpiride administration.
Therefore, it is not clear whether the disturbed LH-RH secretion after estrogen injection in hyperprolactinemic women is caused by a direct action of PRL on the hypothalamus or by ovarian dysfunction with inadequate estrogen production. Further studies are necessary to elucidate the precise mechanism of action of PRL on the positive feedback effect of estrogen on LH-RH release. 
